EnginZyme demonstrates breakthrough piloting results, and opens the path to commercial scale

Cell-free biology

Home » Emerging technologies » Cell-free biology

Debut Biotech Raises $22.6M Series A to Commercialize High-Value Ingredients from Proprietary Cell-Free Biomanufacturing Platform

Novel ingredients bring unique advantages to cosmetic, food, and health and wellness markets in one of the largest Series A financing rounds in synthetic biology space SAN DIEGO (PRWEB) AUGUST 12, 2021 Debut Biotech, a...

The DNA Industry Is Going Cell-Free

OriCiro Launches World’s First Cell-Free Amplification Technology for Large Circular DNA

TOKYO, Sept. 30, 2020 /PRNewswire/ — OriCiro Genomics, a pioneer in the cell-free synthesis and amplification of genome-scale large DNA for gene therapy and synthetic biology, has today launched the OriCiroTM Cell...

EnginZyme demonstrates breakthrough piloting results, and opens the path to commercial scale

Cell-free biology

Debut Biotech Raises $22.6M Series A to Commercialize High-Value Ingredients from Proprietary Cell-Free Biomanufacturing Platform

The DNA Industry Is Going Cell-Free

OriCiro Launches World’s First Cell-Free Amplification Technology for Large Circular DNA

Debut Biotechnology Awarded $1M from Air Force Research Lab to Leverage Cell-Free Continuous Biomanufacturing in Aerospace Applications

EnginZyme Secures €6.4 Million Series A Financing Round Led by Sofinnova Partners

Debut Biotechnology Closes $2.6M Seed Round to Bring Continuous Biomanufacturing of High-Value Molecules to Pharma

Cell-free is growing up

Arbor BiosciencesTM Launches Bulk Offerings of Cell-Free Expression Systems

Revolutionizing large-size DNA amplification: A Q&A with OriCiro Genomics’ Seiji Hirasaki

Why you should look to Tokyo for the cell-free amplification of large, genome-scale DNA

Biology Unlocked: Emerging Applications of Cell-Free Systems

Synthetic biology breaks out of the cell